Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Non-infectious and Idiopathic Uveitis

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the effect of Beta-1,3/1,6-D-Glucan from mycelium extract of Indonesian Ganoderma lucidum as an adjuvant to methylprednisolone for non-infectious and idiopathic uveitis

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Fakultas Kedokteran Universitas Indonesia
• Treatments: Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

1. Patients with non-infectious and idiopathic uveitis.

2. Indicated to receive oral steroid and have signs of anterior segment inflammation.

3. Anterior chamber inflammation >= +2 according to SUN criteria.

4. Age between 18 and 65 years old, good general condition, consented to be involved in the research, and are willing to come regularly according to follow up schedule.

Exclusion Criteria:

1. Received systemic steroid and/other immunosuppressive drugs two weeks before the start of the trial.

2. Received antibiotics one week before the start of the trial.

3. Contraindicated to oral steroid.

4. Other primary ocular disorder, such as glaucoma, anterior segment dysgenesis, or others.

5. Pregnant and nursing women.

6. Patients with history of hypersensitivity/ allergy to Ganoderma species or other fungi.